MD HB417

Medetomidine and xylazine are added to Schedule III of Maryland's Controlled Dangerous Substances Act, placing them alongside substances with moderate abuse potential and accepted medical use

Schedule III classification subjects medetomidine and xylazine to existing criminal penalties and regulatory requirements for controlled substances under Maryland law

The original consumer protection provisions were removed through amendment, including retailer restrictions, age verification requirements, sales recordkeeping mandates, and civil penalties of $3,000-$6,500

Effective date is October 1, 2026